Pediatrix Medical Group (NYSE:MD – Get Free Report) announced its earnings results on Tuesday. The company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04, FiscalAI reports. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. During the same quarter in the previous year, the firm posted $0.53 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis.
Pediatrix Medical Group Price Performance
Shares of MD stock opened at $26.24 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33. The company has a market capitalization of $2.15 billion, a PE ratio of 12.74 and a beta of 0.66. The firm’s 50-day moving average is $24.70 and its two-hundred day moving average is $22.52. Pediatrix Medical Group has a 12 month low of $11.90 and a 12 month high of $27.94.
Insider Buying and Selling at Pediatrix Medical Group
In other news, Director Shirley A. Weis sold 36,028 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total transaction of $855,665.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Pediatrix Medical Group
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $27.00 price target on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a research note on Friday, May 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday, June 24th. Truist Financial raised their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Finally, UBS Group boosted their target price on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $23.33.
View Our Latest Stock Analysis on MD
About Pediatrix Medical Group
Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
See Also
- Five stocks we like better than Pediatrix Medical Group
- Tether Strikes Gold: Crypto’s Physical Pivot
- Jersey Mike’s Serves Fresh Gains After IPO Stumble
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
